Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has announced a new chief content and engagement officer. Maureen Connolly, an award-winning content strategic and audience builder, will step into … Continue reading →

Aditxt Inc. (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, announced that it is working with Riverside Management Group LLC, a merchant banking firm providing investment banking advisory services; RMG … Continue reading →

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced the formation of a U.S.-based wholly owned subsidiary, Pearsanta Inc. The move intends to accelerate the expansion of … Continue reading →

Aditxt (NASDAQ: ADTX) recently announced the formation of a U.S.-based wholly owned subsidiary, Adimune Inc., and appointed Joachim-Friedrich Kapp, MD, Ph.D, a 30-year veteran of the pharmaceutical industry, as its chairman and CEO. “Dr. Kapp will be tasked with leading … Continue reading →

Aditxt (NASDAQ: ADTX), a biotech innovation company, is developing and commercializing technologies with a focus on monitoring and modulating, mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. “In late October 2022, Aditxt announced the … Continue reading →

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, on January 3, 2023 announced the formation of a U.S.-based wholly owned subsidiary, Adimune, Inc. (“Adimune(TM)”). The company also … Continue reading →

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission … Continue reading →

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, is focused on mapping and reprogramming the immune system, designing technologies to provide a personalized immune profile. These technologies … Continue reading →

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating … Continue reading →

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced that its program Adimune(TM) has initiated the GMP manufacturing of drug candidate ADI(TM)-100 as … Continue reading →